How is Cord Blood Processed and Stored

Processing of your baby’s Cord Blood

Stem cell isolation is a critical step in cord blood banking. It affects the number of stem cells that can be harvested or recovered from the cord blood. Cell recovery rates are critical because a higher number of stem cells could enhance the success of the transplant or treatment. That's why Cordlife has invested in the Sepax®2 automated stem cell processing technology, a safe, sterile and fully automated cord blood processing technology – so you get more stem cells for maximum transplant success^.
The first private cord blood bank in Singapore that offers the Sepax®2 automated processing technology, this Swiss-made and U.S. FDA-cleared device can recover as high as 99.46%1 of Total Nucleated Cells (TNC) from cord blood; up to 57%2 cell count higher than other processing methods. It is also a functionally closed processing system which ensures the sterility of the cord blood by eliminating exposure to air contaminants.
References
1. Cordlife umbilical cord blood processing data as at 30 April 2013
2. Valeri et al., Transfusion 1996; 36: 303-8.
sepax2
Sepax®2 Machine

Storing your baby's Cord Blood

Cordlife uses the U.S. FDA approved cryogenic storage pouch. This multi-compartmentalised cryobag has 20% and 80% compartments. This cryobag also has 2 integrally attached segments which are in compliance with AABB and FACT-Netcord standards. This dual compartment addresses the stem cell expansion programmes in future. That means that when this stem cell expansion technology is commercially viable, you can withdraw 80% of the stem cells for immediate use /treatment while continuing to store the 20% balance for later expansion.

The integral segments also provide the safety and assurance that additional product testing is performed on the associated unit thereby eliminating testing and cord blood unit mix ups. This is to allow for additional testing of the sample should it be required in the future, or for viability testing prior to a transplant. This storage pouch is made of a special material designed specifically to withstand cryogenic temperatures.

cryobag
Image 1 - Cordlife's FDA approved dual compartmental storage pouch
with integrated segments (before detachment)

Your baby’s cord blood is stored in vacuum insulated cryogenic storage tanks, and are designed to remain at optimal cryogenic temperature of below -150°C for cell storage over long periods.

Cordlife uses MVE Anti-contamination Vapour-phase Liquid Nitrogen Storage System for long-term stem cell cryopreservation.

Vapour-phase storage is preferred over liquid-phase storage as it eliminates the chance of cross contamination between cord blood units as compared with those stored in liquid nitrogen.

The MVE Anti-contamination Vapour-phase Liquid Nitrogen Storage System operates perfectly, even without electrical supply, and is 100% reliable and failsafe with no chance of robotic malfunction. Unlike other storage systems available in the market today, our tanks have never been recalled by the U.S. FDA or the manufacturer.

Over 99% of private cord blood banks also use only vapour-phase freezers. Presently, the majority of stem cell transplantations used cord blood units stored in vapour freezers.

Cord Blood Storage
Image 2 - MVE Anti-contamination Vapour-phase Liquid Nitrogen Storage at Cordlife storage facility
Reference:
1. Best practices for Repositories I: Collection, Storage, and Retrieval of Human Biological Materials for Research

Related items

  • Potential Applications of Umbilical Cord Lining Stem Cells Potential Applications of Umbilical Cord Lining Stem Cells

    Potential Therapeutic Application

    SourceUmbilical cord lining
    Types of stem cells Mesenchymal stem cells (MSCs) Epithelial stem cells (EpSCs)

    Potential Treatment for

    Tissue repair

    • Myocardial infarction (heart muscle repair)
    • Osteoarthiritis
      (cartilage repair and other orthopedic applications)
    • Stroke
    • Pulmonary fibrosis

    HSCs engraftment support

    • Shorten time of engraftment
    • Reduce immune system complications

    Immune modulation

    • Type 1 diabetes
    • Crohn's disease
    • Graft versus host disease (GvHD)

    Wounds/soft tissue repair

    • Surface ulcers
      (e.g. diabetic ulcers)
    • Various types of burns
    • Tissue trauma
    • Lining of liver
    • Replacement of corneal membrane

    Today, more than 190 clinical trials1 are on-going worldwide to uncover the potential of MSCs. Thus far, encouraging results have been published; stem cell treatments have been proven safe and capable of repairing damage caused by stroke and heart disease. MSCs have also been used in combination with HSCs as a dual therapy to promote faster engraftment of HSCs and to reduce immune system complications2.

    Although there is evidence that MSCs can be changed to certain types of Epithelial cells, the cells cannot be changed into Epithelial stem cells (EpSCs). The difference between Epithelial stem cells and Epithelial cells is that Epithelial stem cells can differentiate into all different epithelial cell types such as skin, cornea, lining of the gut, etc. on demand. Whereas, (non-stem) Epithelial cells have already reached terminal differentiation so the cells cannot be further changed into different Epithelial cell types when needed. Thus, MSCs and EpSCs cannot be replaced by each other.

    1 ClinicalTrials.gov. Accessed on 4 January 2012. (http://www.clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells)
    2 Battiwalla M, Hematti P. 2010. Cytotherapy. 1 January 2010.

    Worldwide researches on diseases treated with MSCs by various Universities or Research Institutions:

    DiseasesName of universities or research Institions
    Stroke University Hospital, Grenobe, France
    Spinal Cord Injury
    • Cairo University, Egypt
    • Chinese University of Hong Kong
    Multiple Sclerosis
    • Spain-Carlos Health Institute
    • University of Cambridge, U.K.
    • Cleveland Clinic, U.S.
    Amylotrophic Lateral Sclerosis Hadassah Medical Organization, Israel
    Parkinson's Disease Jaslok Hospital and Research Centre, India
    Multiple System Atrophy Yonsei University, South Korea
    Liver Disease Cytori Therapeutics, U.S.
    Diabetic Foot Ulcer
    • Third Military Medical University, China
    • Washington DC Veterans Medical Centre, U.S.
    • Ruhr-University Bochum, Germany
    Diabetes
    • FuZhou General Hospital, China
    • Uppsala University, Sweden
  • How Are Stem Cells Used How Are Stem Cells Used

    Stem Cell Transplantation

    This is done to reconstitute a patient's blood and immune system, following treatments such as chemotherapy or radiotherapy, which destroys blood cells.

    The stem cells are infused directly into the patient's bloodstream, which migrate to the bone marrow. Inside the bone marrow environment, the stem cells begin differentiating into the three blood cell types - red blood, white blood and platelets. This initiates the regeneration of the patient's blood and immune system.

    The first cord blood transplant was performed in 1988 in France, which successfully treated a 5-year old boy with Fanconi's Anaemia. To date there have been more than 30,000 cord blood stem cell transplants reported worldwide.1

    Cellular Therapies

    Many newer applications are still undergoing development. In some cases, like spinal cord injury and heart attacks, the cells are directly injected into the damaged tissues. Some of the benefits experienced appear to be due to new blood vessel formation, which restores blood flow to damaged tissue.

    As these treatments develop, we expect to see cord blood stem cells used in different ways. In some cases, the stem cells will be treated in the laboratory to make new cell types before use. In other cases, they will be delivered directly into the damaged tissue.

    View video on "Cordlife's successful transplant to treat leukemia".

    Source:
    Ballen K., Gluckman E., Broxmeyer H. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491-498.
  • Most Advanced Technology Most Advanced Technology

    Sepax®2 - fully automated cord blood processing system

    (only available at Cordlife Singapore)

    Stem cell isolation is a critical step in cord blood banking. It affects the number of stem cells that can be harvested or recovered from the cord blood. Cell recovery rates are critical because a higher number of stem cells could enhance the success of the transplant or treatment.

    That's why Cordlife upgraded from processing cord blood manually to using a fully automated cord blood processing technology to help you maximize your investment. Cordlife is the only cord blood bank in Singapore that offers the world's most preferred fully automated cord blood processing technology, known as Sepax®2.

    Sepax®2 is a Swiss-made and U.S. FDA-cleared device offers safe and sterile technology to recover as high as 99%* of stem cells* from cord blood; up to 52%* higher than other processing methods. The system is functionally closed which ensures the sterility of the cord blood by eliminating exposure to air contaminants.

    Main benefits of Sepax®2

    • Recovers as high as 99%1 of cells2 from cord blood; up to 52%3 higher than other processing methods
    • Consistently high yields, independent of operator skills
    • No sample mix up, only one cord blood unit per processing cycle
    • No cross contamination with other samples
    • Highly sterile

    References
    1Cordlife umbilical cord blood processing data as of 31 December 2010
    2Total nucleated cell. 3Valeri et al., Transfusion 1996; 36: 303-8.

    Sources: www.processedbysepax.com and Biosafe, manufacturer of Sepax® (figures accurate as of 17 November 2008).
  • Protecting 3 Generations of Your Family With Your Baby’s Cord Blood Protecting 3 Generations of Your Family With Your Baby’s Cord Blood

    At Cordlife, we understand that as a parent, you did not have a chance to store your own precious cord blood. That is why, we have extended the biological insurance coverage of storing your baby’s cord blood to 3 generations of your family with CordBlood Network.

    Unlike other cord blood banks that provide basic cord blood banking for only your child, CordBlood Network, a Cordlife initiated programme will assist in the search for a matching cord blood unit should the need arise for your child, his/her biological parents and biological grandparents. With CordBlood Network, you can now protect 3 generations of your family by storing your baby’s cord blood with Cordlife.

    Facts about Cord Blood Banking

    Chances of using stem cells

    • 1 in 217 chance that a person may need cord blood stem cells for treatment in their life time1.
    • 12 cord blood units were releases for transplants and therapeutic applications by Cordlife Group.
    • 73% of cord blood transplants by ViaCord were self-use, 27% were from siblings1.

    Higher chance of finding a match within the patient’s family

    • The odds of finding a match in the same racial group is around 1 in 20.0002.
    • The procurement fee for donated cord blood in Singapore is between $30,000 and $75.0002
    • 25% chance of a 100% match between siblings. A perfect match is required for bone marrow transplants, but not in cord blood transplant3.
    Source
    1. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U. S. Biol Blood Marrow Transplant. 2008;14:316-322.
    2. Joan Chew (July 18, 2013). Criterion for new stem-cell transplant. The Straits Time
    3. National Marrow Donor Program Webiste. www.marrow.org. Accessed April 10, 2014.